Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
A legfontosabb adatok
- Ki végzi
- National Taiwan University Hospital
- Hol
- Tajvan3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 69 fő, tervezett
- Kezdés
- 2026. aug. 1.
- Várható befejezés
- 2035. ápr. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Hypofractionated Adjuvant Proton Therapy
- Hypofractionated Adjuvant Photon Radiation Therapy
- A regiszteradat frissítve
- 2026. július 16.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a thymic epithelial tumor (thymoma or thymic carcinoma) who had surgery to remove the thymus and tumor. They will get a shorter course of radiotherapy after surgery, with photon or proton therapy.
- Életkor
- 18 years and older.
- Nem
- All sexes can join.
- A betegség stádiuma
- Masaoka-Koga stage I to III, confirmed by pathology, with a reason to give radiotherapy after surgery. Karnofsky performance status of 70% or more. Life expectancy of 1 year or more.
- Korábbi kezelés
- Must have had radical thymothymectomy. Earlier induction or neoadjuvant chemotherapy is allowed. No prior radiotherapy to the chest.
- Biomarker vagy leletérték
- Blood tests within 90 days before registration: white blood cell count >= 2000/mm3, platelet count >= 50,000/mm3, hemoglobin >= 8 g/dL, serum creatinine <= 2.0 mg/dL (177 µmol/L) or eGFR >= 30 mL/min, AST/ALT <= 2.5 times the upper limit of normal. Women who can become pregnant need a negative pregnancy test within 14 days before entry.
A részvétel fő kizáró okai
- Prior radiotherapy to the chest.
- Planned chemotherapy at the same time as radiotherapy, or another experimental treatment during radiotherapy.
- Serious active illness, such as infection needing intravenous antibiotics, heart attack or heart failure needing hospital care in the last 6 months.
- Pregnant or breastfeeding women.
- Not willing to use contraception during radiotherapy and for 3 weeks after.
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Thymic epithelial tumor, including thymoma or thymic carcinoma, confirmed by pathology
- Received radical thymothymectomy
- Masaoka-Koga stage I to III disease with an indication for postoperative radiotherapy
- Age >= 18 years
- Karnofsky performance status >= 70%
- Life expectancy >= 1 year
- Sufficient bone marrow reserve, renal function, and liver function within 90 days prior to registration, defined as: white blood cell count >= 2000/mm3; platelet count >= 50,000/mm3; hemoglobin >= 8 g/dL; serum creatinine <= 2.0 mg/dL or estimated glomerular filtration rate >= 30 mL/min; AST/ALT <= 2.5 times the upper limit of normal
- Women of childbearing potential must have a negative qualitative serum or urine pregnancy test within 14 days prior to study entry
- Able to comply with study procedures and follow-up schedules and willing to provide study-specific informed consent
Ki nem vehet részt
- Prior radiotherapy to the thorax
- Severe active comorbidities that, in the judgment of the investigator, make the patient inappropriate for study entry, interfere with safety or adverse event assessment, or limit compliance with study requirements, including: uncontrolled active infection requiring intravenous antibiotics at registration; transmural myocardial infarction <= 6 months prior to registration; unstable angina or congestive heart failure requiring hospitalization <= 6 months prior to registration; life-threatening uncontrolled clinically significant cardiac arrhythmias; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at registration; uncontrolled psychiatric disorder
- Planned receipt of another investigational treatment during radiotherapy
- Planned concurrent chemotherapy during radiotherapy. Prior induction or neoadjuvant chemotherapy, or planned sequential adjuvant chemotherapy after adjuvant radiotherapy, is allowed
- Women of childbearing potential and sexually active male participants who are unwilling or unable to use medically acceptable contraception during radiotherapy and for 3 weeks after completing treatment
- Pregnant or breastfeeding women
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors. The study estimates 5-year local control and prospectively characterizes acute and late treatment-related adverse events, quality of life, cardiopulmonary function, and patterns of failure. Photon therapy and proton therapy are both protocol-acceptable modalities and are selected by shared decision-making rather than randomization.
A vizsgálat csoportja
- Hypofractionated Adjuvant Radiation TherapyA vizsgált kezelés
Participants receive hypofractionated adjuvant radiotherapy after radical thymothymectomy. Photon therapy or proton therapy is selected by shared decision-making between the participant and treating radiation oncologist.
Kezelés: Hypofractionated Adjuvant Proton Therapy és Hypofractionated Adjuvant Photon Radiation Therapy
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Thymic Epithelial Tumor Hypofractionated Adjuvant Radiotherapy (THOR): A Multi-center Single-Arm Prospective Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. július 16.